
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COMTAN | Orion Pharma | N-020796 RX | 1999-10-19 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| STALEVO 50 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD, RS |
| STALEVO 100 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD |
| STALEVO 150 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD |
| STALEVO 200 | Orion Pharma | N-021485 RX | 2007-08-02 | 1 products, RLD, RS |
| STALEVO 75 | Orion Pharma | N-021485 RX | 2008-08-29 | 1 products, RLD |
| STALEVO 125 | Orion Pharma | N-021485 RX | 2008-08-29 | 1 products, RLD |
Brand Name | Status | Last Update |
|---|---|---|
| carbidopa, levodopa and entacapone | ANDA | 2025-11-05 |
| carbidopa, levodopa, and entacapone | NDA authorized generic | 2023-11-30 |
| entacapone | ANDA | 2025-10-01 |
| stalevo | New Drug Application | 2025-11-06 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 4 | 1 | 2 | — | 9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyskinesias | D020820 | — | G24 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Entacapone |
| INN | entacapone |
| Description | Entacapone is a monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group. It has a role as an EC 2.1.1.6 (catechol O-methyltransferase) inhibitor, an antiparkinson drug, a central nervous system drug and an antidyskinesia agent. It is a monocarboxylic acid amide, a nitrile, a member of catechols and a member of 2-nitrophenols. |
| Classification | Small molecule |
| Drug class | catechol-O-methyltransferase (COMT) inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1 |
| PDB | — |
| CAS-ID | 130929-57-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL953 |
| ChEBI ID | 4798 |
| PubChem CID | 5281081 |
| DrugBank | DB00494 |
| UNII ID | 4975G9NM6T (ChemIDplus, GSRS) |











